Clinical Trial Update: Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing anastrozole plus placebo to anastrozole plus gefitinib (ZD1839) in postmenopausal patients with ER/PR-positive metastatic breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Gefitinib (Gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED